Levilimab vs placebo or usual care
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 0.5 [0.05, 5.43]1 study · 206 participantsLow